Genital Neoplasms, Male: Clinical Trials

6,835 trials for Genital Neoplasms, Male, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3252 completed, 1046 recruiting, 748 unknown, 653 terminated. 2062 Phase 2, 1871 Not applicable, 1147 Phase 1, 631 Phase 3, 124 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 22062Completed 1023, Terminated 299, Recruiting 279, Unknown 158, Active not recruiting 154, Withdrawn 82, Not yet recruiting 58, Suspended 7, Enrolling by invitation 2
Not applicable1871Completed 825, Recruiting 313, Unknown 275, Active not recruiting 151, Terminated 109, Not yet recruiting 97, Withdrawn 74, Enrolling by invitation 18, Suspended 9
Phase 11147Completed 592, Recruiting 173, Terminated 154, Active not recruiting 87, Unknown 70, Withdrawn 35, Not yet recruiting 25, Suspended 7, Enrolling by invitation 4
Phase 3631Completed 320, Recruiting 83, Active not recruiting 73, Terminated 64, Unknown 57, Withdrawn 17, Not yet recruiting 13, Enrolling by invitation 2, Suspended 2
Phase 4124Completed 65, Unknown 16, Recruiting 14, Terminated 13, Active not recruiting 6, Not yet recruiting 5, Suspended 2, Withdrawn 2, Enrolling by invitation 1
Early Phase 1108Completed 42, Unknown 18, Recruiting 16, Active not recruiting 9, Terminated 9, Withdrawn 7, Not yet recruiting 6, Enrolling by invitation 1

Follow Genital Neoplasms, Male: new trials by email Literature Review of Genital Neoplasms, Male trials Research Report on Genital Neoplasms, Male

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
(a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment
Not applicableNot yet recruitingAhmadu Bello University892029-03-012026-07-29
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer
Phase 1 / Phase 2Not yet recruitingCHU de Quebec-Universite Laval5002028-03-012025-03-30
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC
Phase 1 / Phase 2Not yet recruitingRegeneron Pharmaceuticals1922027-06-282026-09-30
Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans
Survey - Head and Neck Cancer, Prostate Cancer
Not applicableNot yet recruitingM.D. Anderson Cancer Center942027-03-012026-10-01
iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer
Interviews - Prostate Cancer
Not applicableNot yet recruitingM.D. Anderson Cancer Center402027-01-312026-10-06
HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer
Clomiphene Citrate 25mg - Prostate Cancer
Phase 2Not yet recruitingUniversity of Nebraska832027-01-312026-10-20
Quality and Safety of Real-Time Brachytherapy Treatments: Clinical Implementation of a Multipoint Scintillation Detector for Treatment Monitoring
Brachytherapy treatment monitoring using a plastic scintillation detector - Prostate Cancer, Gynecologic Cancers
Not applicableNot yet recruitingCISSS de Chaudière-Appalaches252027-01-152026-10-21
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group4322027-01-062026-10-01
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
Digital tool using extended reality - Testicular Cancer, Testis Cancer
Not applicableNot yet recruitingGustave Roussy, Cancer Campus, Grand Paris2452027-01-042026-05-06
Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening
Veteran Peer Decision Coaching Session for PSA Screening - Prostate Cancer
Not applicableNot yet recruitingVA Office of Research and Development2282027-01-042026-10-21
ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer
Prostate Cancer
Not yet recruitingAmsterdam UMC, location VUmc1302027-01-012026-10-08
Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention
Cooking Healthy - Engaging Families (CHEF), Control - Neoplams, Prostate Cancer (Adenocarcinoma)
Not applicableNot yet recruitingUniversity of Arizona402027-01-012026-07-14
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
ICG-Guided Retroperitoneal Sentinel Lymph Node Biopsy, Radical Inguinal Orchiectomy - Testicular Cancer, Testicular Germ Cell Tumor
Not applicableNot yet recruitingHeinrich-Heine University, Duesseldorf1712027-01-012026-07-13
Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer
weekly CT or MR online adaptive definitive SBRT - Prostate Cancer
Not applicableNot yet recruitingUniversity of Zurich542027-01-012026-08-21
Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer
Biopsy Procedure, Computed Tomography, Electronic Health Record Review - Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Not applicableNot yet recruitingCity of Hope Medical Center202027-01-012026-08-17
Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization
Prostate Cancer (Diagnosis)
Not yet recruitingChinese University of Hong Kong4002027-01-012026-10-22
PSMA-specific CAR-T Cell Therapy
4SCAR-PSMA T cells - PSMA Positive Tumors or Tumor Tissues
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-08-26
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
Tamoxifen - Hypogonadism, Prostate Cancer
Phase 2RecruitingUniversity Health Network, Toronto962026-12-312026-10-22
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
Prostate-Targeted PET- Scan (P-PET). - Prostate Cancer
Not applicableNot yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's252026-12-302026-09-25
Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer
Aerobic Exercise, Biopsy Procedure, Biospecimen Collection - Colon Polyp, Colorectal Carcinoma
Not applicableRecruitingCity of Hope Medical Center302026-12-162026-08-28

Showing 20 of 6835. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (6444)  ·  Breast Neoplasms (613)  ·  Neoplasms (456)  ·  Ovarian Neoplasms (301)  ·  Testicular Neoplasms (295)  ·  Lung Neoplasms (268)  ·  Neoplasm Metastasis (264)  ·  Colorectal Neoplasms (254)  ·  Pancreatic Neoplasms (204)  ·  Urinary Bladder Neoplasms (204)  ·  Carcinoma, Non-Small-Cell Lung (181)  ·  Uterine Cervical Neoplasms (154)  ·  Colonic Neoplasms (150)  ·  Melanoma (146)  ·  Kidney Neoplasms (142)

Broader conditions

Genital Diseases (6830)  ·  Urogenital Diseases (6827)  ·  Male Urogenital Diseases (6818)  ·  Genital Diseases, Male (6814)  ·  Neoplasms by Site (6811)  ·  Urogenital Neoplasms (6774)  ·  Prostatic Diseases (6444)  ·  Neoplasms (6379)  ·  Pathological Conditions, Signs and Symptoms (877)  ·  Female Urogenital Diseases (758)  ·  Female Urogenital Diseases and Pregnancy Complications (758)  ·  Skin and Connective Tissue Diseases (693)  ·  Skin Diseases (689)  ·  Neoplasms by Histologic Type (684)

Interventions

Docetaxel (308)  ·  Prednisone (254)  ·  enzalutamide (217)  ·  Leuprolide (189)  ·  Radiotherapy (189)  ·  Abiraterone Acetate (182)  ·  Magnetic Resonance Spectroscopy (175)  ·  bicalutamide (143)  ·  Goserelin (140)  ·  Androgen Antagonists (127)  ·  Radiosurgery (113)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (110)  ·  apalutamide (98)  ·  abiraterone (92)  ·  gallium 68 PSMA-11 (84)

Sponsors

National Cancer Institute (NCI) (220)  ·  Memorial Sloan Kettering Cancer Center (150)  ·  M.D. Anderson Cancer Center (128)  ·  University Health Network, Toronto (100)  ·  Mayo Clinic (73)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (73)  ·  AstraZeneca (70)  ·  Jonsson Comprehensive Cancer Center (70)  ·  Dana-Farber Cancer Institute (58)  ·  Novartis Pharmaceuticals (56)  ·  University of California, San Francisco (56)  ·  Bayer (49)  ·  Case Comprehensive Cancer Center (49)  ·  Duke University (48)  ·  Janssen Research & Development, LLC (48)

Countries

United States (3596)  ·  Canada (688)  ·  United Kingdom (479)  ·  France (472)  ·  China (436)  ·  Italy (320)  ·  Germany (311)  ·  Spain (284)  ·  Netherlands (281)  ·  Australia (238)  ·  Belgium (228)  ·  South Korea (185)  ·  Denmark (159)  ·  Sweden (143)  ·  Poland (142)

Top investigators

Rahul Aggarwal, MD (17)  ·  Mary-Ellen Taplin, MD (14)  ·  Michael Morris, MD (13)

Results publications

PMID 34350976, PMID 24722180, PMID 33270906, PMID 41698328, PMID 33465252, PMID 36884035, PMID 38421243, PMID 38421252, PMID 22894553, PMID 25712310, PMID 25819287, PMID 27626136, PMID 29272162, PMID 32994091, PMID 38320143, PMID 22747660, PMID 25592642, PMID 27626365, PMID 37070660, PMID 40016438, PMID 20818327, PMID 21106711, PMID 22129214, PMID 22932804, PMID 24423462, PMID 25614256, PMID 25626035, PMID 25687533, PMID 25754526, PMID 26512712, PMID 27044935, PMID 27339115, PMID 29240541, PMID 31227373, PMID 31375469, PMID 31540791, PMID 32203306, PMID 32878613, PMID 34529005, PMID 35084544, PMID 35643841, PMID 35731340, PMID 36383907, PMID 36596347, PMID 37482512, PMID 38572751, PMID 39606939, PMID 40645505, PMID 12126818, PMID 15470214

NIH funding

2023 (41), P30CA014089 (27), 2017 (26), P30CA033572 (25), 2016 (22), 2019 (22), 2025 (22), P30CA072720 (21), U10CA031946 (20), 2014 (17), P30CA008748 (16), P30CA016672 (16), P30CA022453 (16), P30CA015704 (15), P30CA043703 (15)